α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 229-243

  Daniel, Guillaume ^a   Musso, Alessandra ^a   Tsika, Elpida ^a   Fiser, Aris ^a   Glauser, Liliane ^a   Pletnikova, Olga ^b   Schneider, Bernard L ^a   Moore, Darren J ^a,c  

^a EPFL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Alpha synuclein; ATP13A2; Heavy metals; Kufor Rakeb syndrome; PARK9; Parkinsonism

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; DOPAMINE; HYDROGEN PEROXIDE; LENTIVIRUS VECTOR; MANGANESE; MESSENGER RNA; ATP13A2 PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATP13A2 GENE; CINGULATE GYRUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC NEURODEGENERATION; EXPOSURE; FEMALE; GENE; GENE EXPRESSION; GENE TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARK9 GENE; PARKINSON DISEASE; PLASMID; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SUBSTANTIA NIGRA; VERY ELDERLY; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MIDDLE AGED; PARKINSONIAN DISORDERS; PATHOLOGY; PREGNANCY; SPRAGUE DAWLEY RAT; TISSUE BANK;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; HUMANS; HYDROGEN PEROXIDE; MALE; MANGANESE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PREGNANCY; PROTON-TRANSLOCATING ATPASES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE BANKS;

EID: 84908541837     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.007     Document Type: Article

References (49)

1. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
2. Coune P.G., Bensadoun J.C., Aebischer P., Schneider B.L. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease. J. Parkinsons Dis. 2011, 1:373-387.
3. Covy J.P., Waxman E.A., Giasson B.I. Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. J. Neurosci. Res. 2012, 90:2306-2316.
4. Daher J.P., Pletnikova O., Biskup S., Musso A., Gellhaar S., Galter D., Troncoso J.C., Lee M.K., Dawson T.M., Dawson V.L., et al. Neurodegenerative phenotypes in an A53T alpha-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet. 2012, 21:2420-2431.
5. Decressac M., Ulusoy A., Mattsson B., Georgievska B., Romero-Ramos M., Kirik D., Bjorklund A. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 2011, 134:2302-2311.
6. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., Zufferey R., Trono D., Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 2000, 11:179-190.
7. Dehay B., Ramirez A., Martinez-Vicente M., Perier C., Canron M.H., Doudnikoff E., Vital A., Vila M., Klein C., Bezard E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9611-9616.
8. Di Fonzo A., Chien H.F., Socal M., Giraudo S., Tassorelli C., Iliceto G., Fabbrini G., Marconi R., Fincati E., Abbruzzese G., et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007, 68:1557-1562.
9. Dusonchet J., Bensadoun J.C., Schneider B.L., Aebischer P. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol. Dis. 2009, 35:32-41.
10. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert. Rev. Mol. Med. 2009, 11:e22.
11. Gasser T., Hardy J., Mizuno Y. Milestones in PD genetics. Mov. Disord. 2011, 26:1042-1048.
12. Gaugler M.N., Genc O., Bobela W., Mohanna S., Ardah M.T., El-Agnaf O.M., Cantoni M., Bensadoun J.C., Schneggenburger R., Knott G.W., et al. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012, 123:653-669.
13. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., Caldwell K.A., Caldwell G.A., Cooper A.A., Rochet J.C., et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 2009, 41:308-315.
14. Grunewald A., Arns B., Seibler P., Rakovic A., Munchau A., Ramirez A., Sue C.M., Klein C. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol. Aging 2012, 33:31.
15. Gusdon A.M., Zhu J., Van Houten B., Chu C.T. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis. 2012, 45:962-972.
16. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4:600-609.
17. Kong S.M., Chan B.K., Park J.S., Hill K.J., Aitken J.B., Cottle L., Farghaian H., Cole A.R., Lay P.A., Sue C.M., et al. Parkinson's Disease linked human PARK9 / ATP13A2 maintains zinc homeostasis and promotes alphaSynuclein externalisation via exosomes. Hum. Mol. Genet. 2014, 6:6.
18. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
19. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 1998, 339:1130-1143.
20. Low K., Aebischer P. Use of viral vectors to create animal models for Parkinson's disease. Neurobiol. Dis. 2012, 48:189-201.
21. Mah C., Sarkar R., Zolotukhin I., Schleissing M., Xiao X., Kazazian H.H., Byrne B.J. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum. Gene Ther. 2003, 14:143-152.
22. Matsui H., Sato F., Sato S., Koike M., Taruno Y., Saiki S., Funayama M., Ito H., Taniguchi Y., Uemura N., et al. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Lett. 2013, 587:1316-1325.
23. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28:57-87.
24. Najim al-Din A.S., Wriekat A., Mubaidin A., Dasouki M., Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 1994, 89:347-352.
25. Ning Y.P., Kanai K., Tomiyama H., Li Y., Funayama M., Yoshino H., Sato S., Asahina M., Kuwabara S., Takeda A., et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008, 70:1491-1493.
26. Oueslati A., Schneider B.L., Aebischer P., Lashuel H.A. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:27.
27. Palmgren M.G., Nissen P. P-type ATPases. Annu. Rev. Biophys. 2011, 40:243-266.
28. Park J.S., Mehta P., Cooper A.A., Veivers D., Heimbach A., Stiller B., Kubisch C., Fung V.S., Krainc D., Mackay-Sim A., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat. 2011, 32:956-964.
29. Park J.S., Koentjoro B., Veivers D., Mackay-Sim A., Sue C.M. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. 2014, 15:15.
30. Podhajska A., Musso A., Trancikova A., Stafa K., Moser R., Sonnay S., Glauser L., Moore D.J. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. PLoS One 2012, 7:29.
31. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
32. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
33. Ramonet D., Podhajska A., Stafa K., Sonnay S., Trancikova A., Tsika E., Pletnikova O., Troncoso J.C., Glauser L., Moore D.J. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 2012, 21:1725-1743.
34. Santoro L., Breedveld G.J., Manganelli F., Iodice R., Pisciotta C., Nolano M., Punzo F., Quarantelli M., Pappata S., Di Fonzo A., et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011, 12:33-39.
35. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
36. Schlaudraff F., Grundemann J., Fauler M., Dragicevic E., Hardy J., Liss B. Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol. Aging 2014, 22:016.
37. 2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem. Biophys. Res. Commun. 2009, 383:198-202.
38. Schultheis P.J., Fleming S.M., Clippinger A.K., Lewis J., Tsunemi T., Giasson B., Dickson D.W., Mazzulli J.R., Bardgett M.E., Haik K.L., et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 2013, 22:2067-2082.
39. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., Troconso J.C., Dawson V.L., Dawson T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
40. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
41. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
42. Stafa K., Trancikova A., Webber P.J., Glauser L., West A.B., Moore D.J. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012, 8:9.
43. Tan J., Zhang T., Jiang L., Chi J., Hu D., Pan Q., Wang D., Zhang Z. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J. Biol. Chem. 2011, 286:29654-29662.
44. Tsika E., Glauser L., Moser R., Fiser A., Daniel G., Sheerin U.M., Lees A., Troncoso J.C., Lewis P.A., Bandopadhyay R., et al. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet. 2014, 23:4612-4638.
45. Tsunemi T., Krainc D. Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 2013, 13:13.
46. Ugolino J., Fang S., Kubisch C., Monteiro M.J. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum. Mol. Genet. 2011, 20:3565-3577.
47. Ulusoy A., Decressac M., Kirik D., Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res. 2010, 184:89-111.
48. Usenovic M., Tresse E., Mazzulli J.R., Taylor J.P., Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J. Neurosci. 2012, 32:4240-4246.
49. Usenovic M., Knight A.L., Ray A., Wong V., Brown K.R., Caldwell G.A., Caldwell K.A., Stagljar I., Krainc D. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum. Mol. Genet. 2012, 21:3785-3794.